RC-106

RC-106 is a novel dual-action small molecule modulator targeting both Sigma-1 (S1R) and Sigma-2 (S2R) receptors. Developed by researchers at the University of Pavia and the Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (I.R.S.T.), it is being investigated for its antitumor activity in highly malignant tumors, specifically glioblastoma and pancreatic cancer. RC-106 demonstrates preferential accumulation in the brain and pancreas following systemic administration. Its mechanism of action involves the inhibition of cell proliferation, induction of apoptosis via caspase 3 and 9 activation, and modulation of the Akt signaling pathway. Preclinical studies using 3D primary cultures and animal models have shown that RC-106 can significantly reduce the growth of human glioblastoma and pancreatic cancer spheroids and impair the clonogenic ability of tumor cells.